1. | buyermode474 | |
2. | RobinFromTheHood | |
3. | ColoradoColo | |
4. | sydavy |
1. | buyermode474 | |
2. | RobinFromTheHood | |
3. | ColoradoColo | |
4. | sydavy |
1. | buyermode474 01/19/2018 Phase Ib2 data announced |
2. | RobinFromTheHood 03/21/2018 Announces the publication of long-term follow-up results from Study 902, where patients were treated with ti… |
3. | buyermode474 02/12/2018 Announces FDA has granted Orphan Drug Designation to its ABO-202 program |
4. | RobinFromTheHood 09/25/2017 Positive upward movement |
5. | RobinFromTheHood 09/25/2017 Way Undervalued Has very low expenses EPS=$10, SP=$100+. That is nearly $17 per share in sales along with Europe Based on $25 per share in sales along with Europe. FDA approval=$1.8B |